Drug Trial Radar · NCT07894887
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jun 2029
Study completion Jul 2031
Sponsor
- Lead sponsor
- Editas Medicine, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1/2, two-part trial consisting of an open label dose-escalation part and a randomized, double blind, placebo-controlled part to investigate safety, tolerability, pharmacokinetics, and efficacy with EDIT-401 gene editing in adult male and female participants 18 to 65 years of age who require additional lowering of low-density lipoprotein cholesterol (LDL-C) such as those with clinical diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH).
Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions
Drug: EDIT-401Drug
Intravenous (IV) infusion
PlaceboOther
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 2 years
- Part 2: Placebo-controlled percent change from baseline in serum LDL-CTime frame: Up to day 90
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Clinical Study Center
Charlestown, New South Wales, Australia
Clinical Study Center
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.